Brown Advisory Inc. boosted its position in West Pharmaceutical Services Inc. (NYSE:WST) by 11.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 478,230 shares of the medical instruments supplier’s stock after acquiring an additional 49,797 shares during the quarter. Brown Advisory Inc. owned 0.65% of West Pharmaceutical Services worth $47,484,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in WST. Rhumbline Advisers grew its stake in shares of West Pharmaceutical Services by 9.0% during the first quarter. Rhumbline Advisers now owns 187,897 shares of the medical instruments supplier’s stock worth $16,589,000 after buying an additional 15,558 shares during the last quarter. Comerica Bank grew its stake in shares of West Pharmaceutical Services by 1.6% during the first quarter. Comerica Bank now owns 63,738 shares of the medical instruments supplier’s stock worth $5,848,000 after buying an additional 996 shares during the last quarter. Intermede Investment Partners Ltd acquired a new position in shares of West Pharmaceutical Services during the first quarter worth $22,179,000. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of West Pharmaceutical Services by 53.0% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 1,994 shares of the medical instruments supplier’s stock worth $176,000 after purchasing an additional 691 shares during the period. Finally, Trexquant Investment LP lifted its holdings in shares of West Pharmaceutical Services by 219.4% during the first quarter. Trexquant Investment LP now owns 11,066 shares of the medical instruments supplier’s stock worth $977,000 after purchasing an additional 7,601 shares during the period. 94.71% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have recently commented on WST shares. Zacks Investment Research lowered shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a report on Saturday, May 5th. ValuEngine upgraded shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Tuesday, June 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. West Pharmaceutical Services currently has an average rating of “Hold” and a consensus price target of $108.33.

Shares of NYSE:WST opened at $117.16 on Wednesday. The firm has a market cap of $8.59 billion, a PE ratio of 42.30, a price-to-earnings-growth ratio of 3.96 and a beta of 1.16. The company has a current ratio of 2.67, a quick ratio of 1.94 and a debt-to-equity ratio of 0.15. West Pharmaceutical Services Inc. has a 52 week low of $82.74 and a 52 week high of $118.05.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, July 26th. The medical instruments supplier reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.03. The company had revenue of $447.50 million for the quarter, compared to analyst estimates of $422.57 million. West Pharmaceutical Services had a net margin of 8.99% and a return on equity of 15.38%. West Pharmaceutical Services’s revenue was up 12.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.66 earnings per share. equities analysts anticipate that West Pharmaceutical Services Inc. will post 2.82 earnings per share for the current year.

In related news, SVP Karen Flynn sold 20,458 shares of the business’s stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $116.23, for a total value of $2,377,833.34. Following the transaction, the senior vice president now owns 31,051 shares in the company, valued at $3,609,057.73. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO William J. Federici sold 42,869 shares of the business’s stock in a transaction on Friday, June 8th. The shares were sold at an average price of $96.09, for a total transaction of $4,119,282.21. Following the completion of the transaction, the chief financial officer now owns 270,681 shares in the company, valued at approximately $26,009,737.29. The disclosure for this sale can be found here. In the last quarter, insiders have sold 68,327 shares of company stock worth $6,983,316. 2.70% of the stock is owned by company insiders.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Read More: Stock Symbols Definition, Examples, Lookup

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.